Acarix AB (SE:ACARIX)
:ACARIX
Want to see SE:ACARIX full AI Analyst Report?
Top Page
Acarix AB
(ACARIX)
Select Model
Select Model
Rating:46Neutral
Price Target:
kr0.27
▼(-5.36% Downside)
Action:Reiterated
Date:05/21/26
The score is primarily held back by very large ongoing losses and sustained negative free cash flow, which imply continued financing risk. Offsetting positives include improving revenue and gross margin and an essentially debt-free balance sheet, while technicals are mostly neutral and valuation metrics are constrained by negative earnings and no stated dividend yield.
Positive Factors
Debt-free balance sheet
An essentially debt-free balance sheet materially lowers refinancing and interest-rate risk and preserves flexibility. This conservative financing gives management room to fund commercialization or bridge capital needs without immediate leverage, supporting durable optionality for scaling.
Negative Factors
High cash burn
Large negative operating and free cash flow indicate persistent cash burn and ongoing financing needs. This creates material execution risk: the company must secure additional capital or quickly improve cash generation, or face dilution, constrained investments, and pressure on commercialization plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
An essentially debt-free balance sheet materially lowers refinancing and interest-rate risk and preserves flexibility. This conservative financing gives management room to fund commercialization or bridge capital needs without immediate leverage, supporting durable optionality for scaling.
Read all positive factors
Acarix AB (ACARIX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr303.30M
Dividend YieldN/A
Average Volume (3M)1.57M
Price to Earnings (P/E)―
Beta (1Y)-0.24
Revenue Growth26.25%
EPS Growth43.03%
CountrySE
Employees8
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,123,320,200
10 Day Avg. Volume1,780,482
30 Day Avg. Volume1,572,056
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)7.91
Price to Sales (P/S)41.02
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr19.80M
Acarix AB Business Overview & Revenue Model
Company Description
Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases in Germany, Sweden, the Middle East, Switzerland, Austria, and internationally. The company offers CADScor System, a non-invas...
How the Company Makes Money
Acarix makes money primarily by selling and commercializing its CADScor System to healthcare providers. Revenue is generated from (1) sales of CADScor System hardware and related components and (2) recurring sales tied to system usage, such as sin...
Acarix AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.05M | 7.36M | 6.20M | 6.24M | 5.82M | 3.76M |
| Gross Profit | 5.29M | 2.76M | 5.59M | 5.30M | 4.62M | 2.82M |
| EBITDA | -38.53M | -44.53M | -62.63M | -77.12M | -76.12M | -50.52M |
| Net Income | -42.76M | -48.09M | -66.19M | -77.84M | -76.98M | -51.80M |
Balance Sheet | ||||||
| Total Assets | 43.50M | 48.33M | 80.76M | 62.88M | 69.48M | 118.60M |
| Cash, Cash Equivalents and Short-Term Investments | 25.79M | 18.27M | 53.99M | 35.15M | 11.31M | 15.81M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 251.00K | 523.00K |
| Total Liabilities | 6.55M | 10.16M | 5.06M | 11.00M | 17.66M | 18.06M |
| Stockholders Equity | 36.96M | 38.17M | 75.70M | 51.88M | 51.83M | 100.54M |
Cash Flow | ||||||
| Free Cash Flow | -37.37M | -49.14M | -64.25M | -81.37M | -75.02M | -48.05M |
| Operating Cash Flow | -35.60M | -48.38M | -63.33M | -81.37M | -74.87M | -48.01M |
| Investing Cash Flow | -476.00K | -757.00K | -920.00K | 0.00 | -151.00K | -43.00K |
| Financing Cash Flow | 16.99M | 11.11M | 86.98M | 106.23M | 69.03M | -164.00K |
Acarix AB Technical Analysis
Negative
0.28
Price Trends
0.28
Negative
0.27
Negative
0.29
Negative
Market Momentum
>-0.01
Negative
46.53
Neutral
61.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACARIX, the sentiment is Negative. The current price of 0.28 is above the 20-day moving average (MA) of 0.27, above the 50-day MA of 0.28, and below the 200-day MA of 0.29, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.53 is Neutral, neither overbought nor oversold. The STOCH value of 61.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACARIX.
Acarix AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | kr428.92M | -5.61 | -27.25% | ― | -4.08% | 1.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr546.68M | -25.75 | -2.52% | ― | -10.66% | 73.69% | |
48 Neutral | kr715.33M | -7.33 | -36.55% | ― | 48.53% | 17.86% | |
46 Neutral | kr303.30M | -8.89 | -104.38% | ― | 26.25% | 43.03% | |
45 Neutral | kr319.06M | -7.16 | -27.22% | ― | -14.57% | 16.16% | |
45 Neutral | kr459.10M | -15.31 | ― | ― | 13.96% | 20.18% |
* Healthcare Sector Average
SE:ACARIX
Acarix AB
0.27
0.04
16.59%
SE:SEZI
Senzime AB
4.57
-0.13
-2.87%
SE:BACTI.B
Bactiguard Holding AB
15.90
-19.10
-54.57%
SE:BRAIN
BrainCool AB
0.81
-0.66
-45.07%
SE:MNTC
Mentice AB
15.40
0.67
4.54%
SE:OSSD
OssDsign AB
4.10
-8.71
-68.01%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.